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INTRODUCTION 
THE ANTIHYPERTENSIVE FUNCTION OF THE KIDNEY 
The role of the kidney in the pathogenesis of hypertensive 
states has been the subject of considerable discussion and 
controversy. In 1898, Tigerstedt and Bergman noted that saline 
extracts of the kidney, when injected into rabbits, elicited a 
pressor response. In 1940, Goldblatt demonstrated that surgical 
stenosis of a renal artery resulted in elevated blood pressure 
thereby linking the kidney with the production of hypertension. 
It was not until 1944, however, that Goormaghtigh, having the 
benefit of Ruyter's earlier description of the juxtaglomerular 
apparatus (1925) suggested that these juxtaglomerular cells 
were the source of renin, the vasopressor inducing substance. 
From other studies, (Kohlstaedt, Helmer and Page, 1938) it became 
evident that renin functioned as an enzyme acting on a component 
of plasma to produce the elevation of blood pressure. This 
renin substrate was named angiotonin by Page and Helmer (1940) 
and hypertensin by Braun-Menendez, et. al. (1940), in whose 
laboratories it was independently characterized. By agreement 
the name angiotensin was later adopted as the plasma component 
directly responsible for the increase in vasomotor tone in 
response to renal artery stenosis (Braun-Menendez and Page, 1958). 
With continued study of the role of the kidney in regulating 
blood pressure it became apparent that functional renal tissue may 
also serve an anti-hypertensive function. Fasciolo, Houssay 
and Tsquini (1938) and Goldblatt (1940) noted the ability of a 
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normally functioning kidney to blunt the rapid increase in blood 
pressure usually seen in response to contralateral renal artery 
stenosis. The blood pressure raising effect of renin given 
intravenously was shown to be potentiated by prior bilateral 
nephrectomy thus suggesting the loss of an anti-hypertensive 
agent produced by the kidney (Harrison, Grollman, and Williams, 
1939). The administration of plasma from an animal with normally 
functioning kidneys was shown to reduce this sensitivity to renin 
in the anephric animal (Page and Helmer, 1940). Page later 
showed that the administration of renin to rats until the point 
of tachyphylaxis resulted in the release of an anti-pressor 
substance into the blood (Page, et.al., 1941). Numerous investigators 
reported that blood pressure was lowered in hypertensive and 
normotensive animals given saline extracts of normal renal tissue 
(Williams, Grollman, and Harrison, 1940; Grollman, Williams, and 
Harrison, 1940a, 1940b; Murphy, et.al., 1942; Stevens, 1946; 
Goldblatt, 1947). Characterization of the vasodepressor substance 
in these extracts was incomplete, however, as was the location 
of its intrarenal synthesis. These studies suggested that the 
kidney contained, and perhaps released, an anti-hypertensive agent. 
The finding of hypertension in rats after bilateral nephrectomy 
(Braun-Menendez and Von Euler, 1947; Grollman, et.al., 1949) 
provided the model for further investigation of the factor responsible 
for the antipressor function of renal tissue. Kolff (1958) and 
Kolff and Page (1954) demonstrated that the perfusion of normal 
kidneys within the circulatory system of these renoprival hypertensive 
animals resulted in restoration of normal blood pressure. It was 
' 
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not necessary that this kidney tissue function in excretion since 
anastarnosis of the ureter to the inferior vena cava permitted an 
identical return of the blood pressure to normal (Kolff, 1958; 
Braun-Menendez, 1958; Muirhead and Stirman, 1958; Toth and 
Bartfai, 1961). The serum of such renoprival rats was found to 
cause venoconstriction when compared with the serum of normal 
animals or from rats with non-excreting functional renal tissue. 
It was suggested, therefore, that the renoprival animal may 
lack a humoral vasodilating substance produced by the kidney 
(Rondel!, McVaugh, and Bohr, 1958). 
Muirhead and colleagues in a series of elegant studies 
(Muirhead, et.al., 1956, 1960a, 1960b, 1960c, 1962, and 1971) 
showed that the renal tissue need not be structurally intact to 
exert its vasodilating or antihypertensive role. Using intra- 
peritoneal or intravenous injections of fragments of whole 
kidneys or medullary or cortical sections of the kidneys suspended 
in saline, they found that after 4 days, rats without kidneys 
developed hypertension. Animals receiving fragments of whole kidney 
tissue or renal medulla, however, did not develop elevated blood 
pressures. Of special significance was the finding that renal 
cortical tissue provided no protection whatsoever from the develop¬ 
ment of elevated blood pressures. Histologic examination of the 
omentum and mesentary of animals which received intraperitoneal 
injections revealed islands of epithelial and stromal interstitial 
cells without evidence of viable juxtaglomerular cells. 
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Studies of the chemical nature of the extracts of renal 
tissue which produced lowering of blood pressure in various 
hypertensive states (Muirhead, et.al., 1960b) revealed that 
the active principle possessed the following characteristics: 
1. Loss of activity at alkaline pH (greater than 10) for 
one hour (Hamilton and Grollman, 1958; Hickler, et.al., 1963; 
Hickler, et.al., 1964a). 
2. Stable at acid pH (less than 2) for one hour (Hickler, 
et.al., 1964b). 
3. Soluble in chloroform (Hickler, et.al., 1964b). 
4. Soluble in ethanol (Muirhead, et.al., 1961; Lee, et.al., 
1963). 
5. Unstable at temperatures greater than 50°C (Hamilton and 
Grollman, 1958; and Lee, et.al., 1963). 
6. Not a polypeptide, resistant to protein hydrolases, 
trypsin and carboxypepsidase (Muirhead, et.al., 1963; Lee, et.al., 
1963; Hickler, et.al., 1964b). 
7. No ultraviolet light absorption at greater than 240 
millimicrons (Muirhead, et.al., 1963). 
8. Not a nucleotide (Lee, et.al., 1963). 
9. Not bradykinin (Hickler, et.al., 1963). 
10. Polyunsaturated lipid with ketone and hydroxyl functional 
groups (Lee, et.al., 1964; Hickler, et.al., 1964b). 
11. Not a natural free fatty acid, glyceride, or phospholipid 
(Hickler, et.al., 1964a, 1964b). 
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12. Molecular weight less than 4500 (Lee, et.al., 1962; 
Muirhead, et.al., 1962; Lee, et.al., 1963; Hickler, et.al., 1964b). 
13. Found exclusively in the medullary tissue of the kidney 
(Hickler, et.al., 1964b). 
The prostaglandins, fatty acids found in many tissues, share 
the above mentioned characteristics. 
THE PROSTAGLANDINS - RENAL VASODEPRESSOR LIPIDS 
In 1965, Lee and co-workers reported the isolation of 3 
vasoactive lipids from renal tissue, two of these were identified 
as prostaglandin E^ (PGE2) and prostaglandin F£a (PGF2a) both of 
which had been previously noted to be present in seminal fluid 
(von Euler, 1934). The other substance, which was a potent 
vasodilator, was named prostaglandin E-217, because of its chemical 
similarity to the E-type prostaglandins and its absorption peak 
at 217 millimicrons. Lee gave this substance the name "medullin" 
although it was later identified as a new prostaglandin and 
designated as prostaglandin A2 (PGA2). Further investigation 
revealed that these prostaglandins were found only in the renal 
medulla but not the renal cortex (Lee and Crowshaw, 1968; Horton 
and Jones, 1968), consistent with the previous findings on the 
location of the vasoactive substance(s). 
The prostaglandins have been the subject of intensive 
investigation in the past decade, and since the entire spectrum of 
their chemistry and physiological actions have recently been 
reviewed (Weeks, 1972; Hinman, 1972), only a brief description of 

some of their characteristics will be given here. It would, 
however, be of value to summarize those characteristics relating 
to the vasomotor effects of these compounds. The three major 
prostaglandins are named A, E, and F according to the chemical 
nature of the cyclopentane ring portion of the molecule. Prosta¬ 
glandins of the A series are derived by the dehydration of the E 
series, and the B series, formed from A by rearrangement of the 
double bond within the cyclopentane ring. In the enzymatic 
metabolism of PGA, PGB is formed via an intermediate molecule, 
PGC, which then rearranges to yield PGB. Prostaglandins of the 
A and E series are vasodepressor in action when administered 
intraarterially, while prostaglandin F is a vasopressor; prosta¬ 
glandin B has little vasoactivity (Lee, 1967). Prostaglandins 
of the E and F series are potent smooth muscle stimulants, while 
prostaglandin A has little smooth muscle stimulating activity 
(Lee, 1967). 
Because of their vasodilating action and antagonism of the 
vasoconstriction produced in response to angiotensin, norepinephrine, 
or renal nerve stimulation it was thought that either prostaglandin 
A or prostaglandin E may be the circulating anti hypertensive 
substance produced by the kidney (Lee, 1969; McClatchey and Carr, 
1971; McGiff, et.al., 1970). Studies on the metabolism of 
prostaglandins revealed that PGA2 was most likely to have a major 
circulating function since greater than 85% of PGEo was metabolized 
and inactivated during one circulation through the lungs and liver, 
whereas less than 30% of PGA was similarly inactivated 
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(McGiff, et.al., 1969b). 
The survival of renal interstitial cells after renal tissue 
fragmentation and intraperitoneal injection led to study of these 
cells as the source of the antihypertensive prostaglandins. Nissen 
reported the presence of lipid granules in these cells (Nissen, 1968a), 
and furthermore, noted an increase in the number of lipid droplets 
after salt loading. This increase in granule number was thought 
to be the result of increase storage of lipid molecules with a 
decrease in the rate of lipid release under salt loading (Nissen, 
1968b; Osvaldo, and Latta, 1966). The successful isolation and 
growth of these cells in tissue culture revealed prostaglandins A^, 
E2* and F2a as components of their lipid content (Muirhead, et.al., 1972b). 
It was shown by numerous investigators (Johnston, Herzog, 
and Lauler, 1967; Vander, 1968; Carriere, Friborg, and Guay, 1971; 
Martinez-Maldonade, et.al., 1972; Lee, 1972a) that infusions of 
prostaglandins A or E into the renal artery resulted in a marked 
increase in sodium, potassium and chloride excretion, glomerular 
filtration rate, and renal blood flow. Furthermore, it was shown 
by McGiff and colleagues (1970a) that the infusion of angiotensin II 
into the renal artery resulted in the release of prostaglandin-like 
material into the renal venous effluent. These observations suggested 
that alterations in sodium intake with resultant changes in renin- 
angiotensin levels may effect the synthesis and release of 
prostaglandins from the kidney. Lee (1972b) has suggested that 
prostaglandin A is a circulating anti-hypertensive natriuretic hormone. 
■ 
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PURPOSE OF THIS INVESTIGATION 
Although a hormone-like action has been suggested for 
prostaglandin A it has been difficult to demonstrate such a 
relationship because of the lack of a rapid, and reliable method for 
the measurement of PGA in biological samples. The first purpose of 
this investigation was, therefore, to develop a radioimmunoassay 
for the rapid determination of PGA content in the numerous samples 
required for physiological studies. Once developed the assay was 
used to study the effect of sodium intake on plasma prostaglandin 
levels in man, and on plasma and renal prostaglandin levels in 
normal and spontaneously hypertensive rats. In an effort to 
establish the role of PGA in vasomotor tone plasma prostaglandin 
A levels in hypertensive patients were measured and a model for 
the regulation of blood pressure and sodium balance was developed. 
EXPERIMENTAL STUDIES 
RADIOIMMUNOASSAY OF THE A PROSTAGLANDINS 
One of the major factors limiting the full evaluation of 
prostaglandins as regulators or mediators of various physiologic 
processes has been the lack of a simplified assay with sufficient 
sensitivity, precision, and specificity to allow the measurement 
of the different classes of prostaglandins in biological samples. 
Recently, radioimmunoassay procedures have been reported for the 
F prostaglandins (PGF) (Caldwell, et.al., 1971) which have largely 

overcome these limitations. However, no such method has been 
reported fcr the A prostaglandins (PGA). Numerous protocols for 
the extraction, isolation, and purification of the A prosta¬ 
glandins and a wide variety of methods for their quantification 
have been reported. These include: thin layer chromatography 
(Horton, and Thompson, 1964), gas liquid chromatography (Ramwell, 
et.al., 1968), radiogas chromatography (Hamberg, 1968), biological 
assay (Vane, 1969), enzymatic assay (Anggard, 1966), and ultraviolet, 
infrared, nuclear magnetic resonance, and mass spectroscopy 
(Thompson, Los, and Horton, 1970). Despite the variety of techniques 
it has not been possible, until this time to measure the A prosta¬ 
glandins in the large numbers of samples required for clinical and 
laboratory studies. Therefore a radioimmunoassay for the A 
prostaglandins was developed using antibodies prepared by immunization 
of rabbits with a bovine serum albumin-prostaglandin E2 conjugate. 
Materials and Methods 
Prostaglandin E2 was covalently linked to bovine serum 
albumin by reaction with carbodiimide reagent as previously 
described for preparing similar conjugates with prostaglandin F 
(Caldwell, et.al., 1971). Considerable conversion of the BSA-PGE to 
BSA-PGA probably occurred during the coupling reaction, or through 
metabolism in the immunized animal. A study of the relative 
specificity of the antiserum showed the greatest affinity for PGA2 
(Figure 1, Table 1), therefore this antiserum will be referred to 

































1 mg of the conjugate divided into 4 injections, administered 
subcutaneously as an emulsion with saline and Freunds Complete 
Adjuvant (1:1). Monthly boosters were given without the Freunds 
complete adjuvant. The animals were bled periodically 10-16 days 
after the fourth and subsequent monthly immunizations. 
Figure 1. Cross reactions of various prostaglandins with an 
antiserum to prostaglandin A at a dilution of 1/400. 

TABLE 1 




TO DISPLACE 50% 






pga2 0.32 ng 100 
0 
II . 
PGA, 0 60 ng 53.3 
0 
II ,.^^^^co2h 
pge2 1.22 ng 26.2 
0 
II 
OH H OH 
PGE, 1.68 ng 19.0 
0 
ii ..^^^co2h 
OH H OH 
P6B 2 2.00 ng 16.0 
OH 
PGFgo 500.0 ng 0.06 
OH 
OH H OH 
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Extraction and Separation of the A Prostaglandins from Plasma 
A flow sheet detailing the method is shown in Figure 2. To each 
10 ml glass stoppered extraction tube, approximately 800 cpm PGA-j-^H 
was added in 0.1 ml ethanol and dried under air. One ml of plasma 
was added to the tube and gently vortexed to ensure solubility of 
the trace. The sample was brought to pH 3.5 with 0.1 ml of 1 N_ HCL. 
The sample was vigorously extracted twice with 5 ml of redistilled 
ethyl acetate (Mallinckrodt, Analytical Reagent), and the tube 
centrifuged at 1,200 x g for 5 min. The ethyl acetate was removed 
and dried in a conical centrifuge tube. The efficiency of the 
extraction process was 90-95%. 
The following solvent systems were prepared for chromatographic 
separation. In each case, spectroquality reagents were used fresh, 
and the ethyl acetate was redistilled to improve its purity. 
Solvent 1: Benzene-Ethyl Acetate (60:40) 
Solvent II: Benzene-Ethyl Acetate-Methanol (60:40:2) 
Solvent III: Benzene-Ethyl Acetate-Methanol (60:40:20) 
Brock minicolumns (1.0 x 15.0 cm glass, Macalaster-Bicknell, 
New Haven, Conn.) were packed with a slurry of 0.5 gms silicic acid 
(100 mesh, Mallinckrodt) in Solvent II. A small piece of glass 
fiber filter paper was inserted in the bottom of the column. Each 
column was washed with 5 ml of Solvent II before the sample was 
applied in 1.0 ml of Solvent II. Benzene (1 ml) was added and 
the eluate discarded, then 0.25 ml of Solvent I was added and the 
eluate discarded. Four ml of Solvent I was added next and the eluate 




FLOW SHEET FOR RADIOIMMUNOASSAY OF A PROSTAGLANDINS 
1 ml PLASMA 
800 cpm PGA-j- H 
0.1 ml 1 N HCL 
EXTRACT 
2 x WITH 5 ml ETHYL ACETATE 
l 
POOL EXTRACTS IN CONICLE TUBE 
1 
APPLY TO COLUMN 
COLUMN 
0.5 gm SILICIC ACID 
SLURRIED IN SOLVENT II 
SOLVENTS 
I. BENZENE/ETHYL ACETATE 
60:40 
II. BENZENE/ETHYL ACETATE/METHANOL 
60:40:2 
III. BENZENE/ETHYL ACETATE/METHANOL 
60:40:20 
DRY ELUATE AND ADD 1 ml ETHANOL 
1 
ELUTE COLUMN 
1. 1.0 ml BENZENE - DISCARD 
2. 0.25 ml SOLVENT : [ - DISCARD 
3. 4 ml SOLVENT I - PGA & PGB 
4. 13 ml SOLVENT II - PGE 
5. 4 ml SOLVENT III - PGF 
0.1 ml 0.2 ml 
-1 
0.7 ml 
DRY IN 10 x 75 TUBES ESTIMATION OF RECOVERY 
RADIOIMMUNOASSAY 
0.1 ml BIFFER 
0.1 ml PGA,- 3H (10,000 cpm) 
0.1 ml ANTISERUM 
y 
2 HRS AT 4°C 
Jl.O ml DEXTRAN-COATED CHARCOAL 




was dried under air, and recovery of the 
The elution pattern of prostaglandins A, 
Figure 3. 
tracer PGA-|-3H was 65-75%. 
B, E, and F is shown in 














Figure 3. Elution patterns of prostaglandins A, B, E, and A via 




The assay was performed in 10 x 75 mm glass disposable tubes. 
Stock solutions of PGA2 in buffer were aliquoted in duplicate 
through a concentration of 0.01 to 1.0 ng. The buffer was made up 
as follows: 5.4 g Nab^PO^b^O, 16.4 g Na2HP0/|.7^0, 9.0 g NaCI , 
1.0 g Na Azide, 1.0 g gamma globulin, and 1000 ml distilled water. 
The PGA-containing fraction from the column was dried, dissolved in 
1 ml of ethanol, and 0.1 and 0.2 ml aliquots were taken and dried 
in assay tubes. The remaining 0.7 ml was dried and counted for 
estimation of recovery, which ranged between 65-75%. When all 
sample tubes were dried, 0.1 ml of buffer was added to each tube. 
Antiserum (0.1 ml, 1/400 dilution in buffer) and approximately 
10,000 cpm PGA-j-^H in 0.1 ml buffer were then added to each tube to 
bring the final volume of all tubes to 0.3 ml. The tubes were 
gently vortexed and allowed to equilibrate for at least 2 hours at 
4°C. 
One ml of a buffer solution containing 0.25% charcoal (Norit A) 
and 0.025% dextran (Pharmacia, Upsala, Sweden) was added within 30 
seconds to all tubes in the assay, and 2.5 minutes later the tubes 
were centrifuged at 1200 g for 10 minutes. The supernatant was 
decanted directly into a scintillation vial and 10 ml Aquasol 
(New England Nuclear) added. Radioactivity was determined with 30% 
efficiency in a Packard Scintillation Counter, Model 3375. Sample 
values were determined using a logit plot with linear regression 
analysis (Figure 4). Initial binding in the absence of any standard 
PGA was approximately 50%, while nonspecific binding was always 
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less than 3%. The equation for determination of the logit value is 
1 = (p/100-p), where p = total counts bound (sample) x 100/total counts 
bound (blank). 
Results 
A composite of 6 standard curves obtained via the described 
method shows a significant displacement of a sample containing 20 
pi cograms of PGA2 (Figure 4). When 1 ml of distilled water was 
carried through the method, displacement equivalent to 10-15 pg was 
obtained. 
In order to verify the accuracy and reproducibi1ity of the 
radioimmunoassay, plasma samples were obtained from patients taking 
indomethacin for the treatment of rheumatoid arthritis. The 
samples were found to have markedly reduced levels of PGA in 
comparison with normals, and were then considered "blank samples." 
The concentration of PGA in plasma of such patients (N = 7) was 
found to be 0.18 + 0.16 ng/ml (mean + SD). Known quantities of 
PGA2 were added to aliquots of these pooled plasmas and the samples 
assayed. Table 2 shows the correlation between prostaglandin 
added and recovered. Linear regression analysis of this data 
revealed a correlation coefficient of 0.999. The equation of the 


























Figure 4. Standard curve for radioimmunoassay of prostaglandin ^2- 
Each point represents a composite of 6 standard curves 































PROSTAGLANDIN A2 ADDED (ng/ml) 




RADIOIMMUNOASSAY OF KNOWN AMOUNTS OF PGA2 ADDED TO PLASMA 
PG^ADDED 
(ng) 
N PLASMA VOLUME 
(ml) 
PLASMA LEVEL OF PGA MEASURED* 
MEAN + SD 
(ng/ml) 
0 5 1.0 0.12 + 0.04 
0.5 5 1.0 0.42 + 0.03 
1 5 1.0 1.08 + 0.09 
5 5 1.0 4.95 + 0.31 
10 5 1.0 10.00 + 0.30 
50 5 1.0 51.53 + 1.59 
100 5 1.0 96.15+1.42 
* corrected for recovery, uncorrected for plasma endogenous level 
The results of competition studies between PGA-j-^H and 
prostaglandins A2, A-j, E2, E-,, E>2, and F2a are shown in Figure 
1 and Table 1. Absence of the ring double bond and the presence of 
an hydroxyl group at position 11 was found in PGE2 results in 
decreased reactivity in comparison with PGA2> Movement of the 10, 11 
double bond within the ring to the 8, 12 position as seen in PGB2 resulted 
in a further decrease in reactivity in comparison with PGE2. A consistant 
loss of reactivity was also related to the absence of the double bond 
at position 5, 6 (PGA2 and PGE2 vs. PGA] and PGE-j). Finally, a 
hydroxyl function at position 9 in the saturated ring results in the 
■ 
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most marked reduction of the cross reactivity (PGF2a in comparison 
with all above prostaglandins). 
Since the silicic acid chromatography completely separated the 
E and F prostaglandins from the A prostaglandins there is little 
concern with the cross reaction of these substances. PGB, however, 
is not separated from PGA in this system. The lack of prostaglandin 
isomerase in human plasma would suggest that sample contamination 
with PGB is of little consequence in humans (Polet and Levine, 1971). 
This PGB cross reactivity, however, may be of concern in samples 
from animals with high levels of prostaglandin A isomerase (Jones, 
1970; Horton, et.al., 1971). 
Initial studies of prostaglandin A in peripheral plasma of 
normal adults revealed concentrations of 1.39 + 0.55 ng/ml in males 
and 1.62 +0.52 ng/ml in females (mean + SD); this difference is 
not statistically significant. Patients with rheumatoid arthritis 
being treated with indomethacin were found to have concentrations 
of 0.18 + 0.16 ng/ml; this is a significant reduction in PGA 
concentration (p < 0.001) in comparison with normal adults. 
(Figure 6) Further studies in 50 normal humans revealed plasma 
prostaglandin A levels to be 1.51 +0.24 ng/ml (mean + SD), range 
1.04 - 1.87. Plasma PGA levels in six anephric humans were found 
to be 0.19 +_ 0.05 ng/ml (mean + SD), suggesting that the kidney was 
































NORMAL MALES with RHEUMATOID 
MALES ARTHRITIS TREATED with 
j INDOMETHACIN 
-"-p<.001 -1 
Figure 6. Peripheral plasma levels of prostaglandin A in normal males 
and females and males with rheumatoid arthritis treated 
with indomethacin. 

Because of the lack of uniformity in the methods for 
collection of samples for prostaglandin determination, both plasma 
and serum samples were studied in 9 individuals. The results 
(Figure 7) show that there is no consistant alteration in the PGA 
concentration during the clotting process. The level in heparinized 
plasma was found to be 1.15 + 0.40 ng/ml and in serum was found 
to be 1.34 + 0.59 ng/ml (mean + SD). In order to ensure accurate 
determination of PGA levels in biological samples, assays should 
also be completed as soon as possible after sample collection. 
Discussion 
Ever since the report by von Euler (1934) of the isolation 
of vasoactive lipid molecules from seminal vesicle tissue, attempts 
have been made to develop rapid, accurate, and sensitive means 
to measure prostaglandin content in biological samples. The 
radioimmunoassay procedure described in this report now allows 
for the measurement of prostaglandin A levels in plasma or serum 
samples. 
In view of the relatively high levels of PGA found in human 
plasma in this study, and the failure of the pulmonary or hepatic 
circulation to inactivate prostaglandins of the A series to the 
same degree as PGE and PGF, Lee's postulation of a potential 
function for PGA as a circulating vasoailatory hormone may be justified 
Indomethacin is a known prostaglandin synthesis inhibitor (Collier 
1971; Ferriera, Moncada, and Vane, 1971; Vane, 1971; Smith and Willis, 
1971), and treatment of patients with indomethacin on a long term 
basis for the management of rheumatoid arthritis has been shown in 






























Comparison of PGA levels in serum and heparinized plasma 
from the same individual. 
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THE EFFECT OF CHRONIC SODIUM LOADING AND CHRONIC SODIUM RESTRICTION 
ON PROSTAGLANDIN SYNTHESIS AND RELEASE 
In 1965, Lee and co-workers presented evidence that prosta¬ 
glandin E£ (PGE2), and medullin, later renamed prostaglandin ^ (PGA2) 
were present in the renal medulla, the portion of the kidney known 
to have vasodepressor properties (Muirhead, Stinman, and Jones, 1960c). 
Nissen (1968a, 1968b) demonstrated that a period of salt repletion 
in salt depleted rats induced an increase in the number of lipid 
droplets in renal medullary interstitial cells. By use of tissue 
culture techniques it was shown that these renal interstitial cells 
contain prostaglandins A2, E2, and (Muirhead, et.al., 1972b). 
In addition to the presence of prostaglandins in the renal medulla 
increased levels of prostaglandin-like material have been demonstrated 
in renal venous blood in response to a number of physiologic stimuli, 
including renal nerve stimulation (Dunham and Zimmerman, 1970), 
adrenaline (McGiff, et.al., 1972), bradykinin (Lonigro, et.al., 1971), 
angiotensin II (McGiff, et.al., 1970a), and renal ischemia (McGiff, et.al., 
1970e). 
The evidence that prostaglandins were present in the renal 
medulla and seemed to respond to physiologic stimuli led workers 
to study the effect of prostaglandins on blood pressure and renal 
function. Prostaglandins E and A have been shown to increase renal 
blood flow, urine volume, free water clearance, and sodium excretion 
when infused in dogs (Johnston, Herzog, and Lauler, 1967; Vander, 
1968; Carriere, Friborg, and Guay, 1971; Martinez-Maldonada, et.al., 
1972; Lee, 1972a). Renal effects in hypertensive man are similar 
to those in dogs when PGA is infused at low concentrations, however, 
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at higher concentrations a vasodepressor effect predominates 
(Carr, 1970; Westura, et.al., 1970; Lee, Johnson, Smith, and Hatch, 
1972). In addition recent studies in man have indicated that PGA 
increases aldosterone secretion independent of changes in ACTH, 
renin, and serum electrolytes (Fichman, et.al., 1972). 
Thus a growing body of evidence suggests that prostaglandins 
play a role in the regulation of blood pressure and salt and water 
balance. Using the recently developed radioimmunoassay for 
prostaglandins the effect of sodium loading and restriction was 
studied in normal humans, and in spontaneously hypertensive and 
normotensive Wistar rats. 
PLASMA PROSTAGLANDIN A, E, AND F LEVELS IN NORMAL HUMANS 
Materials and Methods 
Experiments were carried out in seven human volunteers from 
whom informed consent was obtained, using a protocol approved by 
the Clinical Investigation Committee of the Yale University School 
of Medicine. 
There were four male and three female volunteers ranging in 
age from 22 to 36 years old. Drugs were not taken during the course 
of the study with the exception of an estrogen-progestin oral 
contraceptive by K.J. None of the subjects had history of serious 
illnesses of any type. One subject (JG) had a questionably enlarged 
liver; his liver function studies were normal. 
The course of the experiments lasted fourteen days during which 
each subject went on three diets; 1) a four day ad-lib dietary 
control period during which the subject ingested his usual daily 
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sodium intake, 2) a five day duration ad-lib diet supplemented by 
six one gram sodium chloride tablets per day, which was calculated 
to yield a total of over 200 mEq sodium intake per day and 3) five 
days of 10 mEq sodium diet prepared bv the metabolic dietary kitchen 
of the Clinical Research Center. In one group of subjects the 
low sodium diet followed the high sodium diet after a one day 
interval (subjects RZ, JG, DS, KJ), in the second group after a 
seven day interval (subjects BK, GD, GS). Potassium and caloric 
intake were not controlled. For comparison to control (ad-lib diet) 
data, only data from the last three days of each experimental period 
were used for calculation of mean prostaglandin levels. "P" values 
were determined by the student t test. 
Blood pressure, weights and blood samples for prostaglandin 
and renin levels were taken daily between 8 and 9 A.M. Blood 
pressures were taken in the sitting position. Blood samples for 
determination of creatinine, electrolytes and hematocrit were 
obtained on the last two days of each experimental diet. Twenty- 
four hour urine collections were made during the last two days of 
each experimental diet period for measurement of sodium, potassium, 
and creatinine excretion. 
Blood for renin determinations was collected in vacutainers 
containing EDTA, blood for prostaglandin in heparinized vacutainers. 
Blood was centrifuged (1200 x g) immediately at 4°C, and after the 
red cells were removed, plasma was stored at -20°C until analysis. 
Sodium and potassium were determined by flame photometry. Creatinine 
was measured on a Technicon Autoanalyzer. Plasma renin activity was 
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measured by radioimmunoassay (Haber, et. al., 1969). 
Prostaglandins were determined by radioimmunoassay. Since 
this method does not distinguish between prostaglandins A-j, E-j and E£, 
or F-j and F2a, the concentrations reported are of the total prosta¬ 
glandins for each type and are designated simply as PGA, PGE, and 
PGF, respectively. Prostaglandin A cannot be separated from 
prostaglandin B by column chromatography. The low cross reactivity 
of the antiserum with PGB in comparison with PGA and the lack of 
an enzyme system in humans to convert PGA to PGB in the plasma 
indicates that contamination of the sample with prostaglandin B 
is of minor concern. 
Results 
A summary of measurements of blood pressure, serum sodium, 
serum potassium, serum creatinine, creatinine clearance, sodium 
excretion, weight, and plasma renin activity is shown in Table 3. 
High Salt Diet 
The high salt diet led to an increase in weight in all 
subjects except GS. The mean increase for the group was 1.1% of control 
body weight (p < .04). This was associated with increased urinary 
sodium excretion from an average baseline of 151 rnEq/day to an average 
of 230 rnEq/day. There was no significant change in blood pressure 
or in serum sodium or potassium concentrations. Although serurn 
creatinine did not change significantly, creatinine clearance 
increased from 117.8 cc/min. to 130.7 cc/min. (p < 0.03). 
As expected, plasma renin activity was lower during the high 
salt diet than during ad-lib or low salt diet in every subject. 
. - 
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Low Salt Intake 
The 10 mEq sodium diet led to a mean weight loss of 3.7%. 
Systolic, diastolic and mean blood pressures fell in every individual, 
averaging 4.5, 3.4 and 3.7% decrease from baseline values respectively. 
Mean serum sodium fell 2.3 mEq/L, (p < 0.002) but serum potassium 
did not change from control levels. Every subject reached urinary 
sodium outputs of less than 10 mEq/day by the fifth low sodium day 
except GS who excreted 21 mEq/24 hours. Mean serum creatinine rose 
significantly from 0.96 to 1.15 mg% (p < 0.02). Renin levels rose 
over baseline values in every subject during salt restriction. 
Prostaglandin A 
Mean plasma concentrations of Prostaglandin A for four ad-lib 
control days and for the last three days of each experimental 
period are shown in Table 4 and Figure 8. 
During the ad-lib sodium intake mean plasma PGA was 1.60 ng/ml. 
The level fell almost 50% during the high sodium diet to a mean of 
0.82 ng/ml. During the low sodium diet PGA levels rose approximately 
34% over baseline, and 161% over high sodium intake to 2.15 ng/ml. 
These changes were significant at p < 0.001. 
Sequential changes of PGA are shown on a daily basis in Figure 9. 
In every subject PGA levels dropped dramatically during the second 
day of the high salt diet and plateaued at this new level. The effect 
of low sodium intake of PGA levels is somewhat more gradual, although 
this could reflect the effect of the prior salt load. However, there 
was no difference in the rate of change of PGA in subjects in whom 
low salt diet immediately followed high salt diets and in those 
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subjects in whom the two dietary periods were separated by six 
days. If prior salt loading had an effect on PGA levels during 
sodium deprivation, one would expect a difference in the two 
groups of subjects since it would seem likely that at least in the 
second group, control conditions would have been re-established. 
Plasma PGA levels rose during the low sodium diet and 
plateaued during the fourth day in most subjects, although the 
mean for the dietary period was determined from the last three 
days for statistical purposes. In one subject (DS) the levels 
of PGA did not rise significantly for the period as a whole. We 
cannot ascribe this response to dietary indiscretion since other 
parameters changed in expected fashion during this period in this 
subject. 
Prostaglandin E and F 
Neither prostaglandin E nor F changed significantly during 
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EFFECT OF SODIUM INTAKE ON PLASMA 
PROSTAGLANDIN LEVELS 
ng/ml 
Figure 8. Effect of sodium intake on plasma prostaglandin A, E, 
and F concentrations in normal humans on high, low, and 






















EFFECT OF SODIUM INTAKE ON PLASMA PROSTAGLANDIN A 
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DAY OF STUDY 
Figure 9. Effect of sodium intake on daily plasma prostaglandin A 
concentrations in normal humans. Day-to-day levels of 
prostaglandin A in peripheral plasma of seven normal human 
volunteers on high, low, and ad-lib sodium intake diets. 
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PLASMA AND RENAL PROSTAGLANDIN A LEVELS IN SPONTANEOUSLY HYPERTENSIVE 
AND NORMOTENSIVE WI STAR RATS 
Materials and Methods 
Normotensive and spontaneously hypertensive wistar rats 
(Okamoto and Aoki, 1963) weighing 330-380 grams, were placed on high, 
low, and normal sodium diets. The composition of the diets has 
been described (Manitus, et.al., 1960). The three diets were: 
1. Normal sodium intake - a diet containing 102 mEq sodium per 
kilogram; distilled water was used for drinking, 2. Low sodium 
intake - a diet containing no measurable sodium content; distilled 
water was used for drinking, 3. High sodium intake - a diet 
containing 102 mEq sodium/kg and 0.9% sodium chloride was the drinking 
solution. Rat weight, food intake, and blood pressure was monitored 
on each sodium intake diet. 
After two weeks on one of the above diets, the animals were 
sacrificed by decapitation, and blood collected using sodium EDTA 
as the anticoagulant, centrifuged (1200 X g at 4°C), and the plasma 
stored at -20°C. The kidneys were removed, cleaned of fat, and 
weighed; each kidney was homogenized in ten milliliters of saline. 
O 
H-PGA-j (New England Nuclear, specific activity 50-60 microcuries/ 
millimole) was added to allow for calculation of total PGA recovery 
after homogenization and assay. 
Prostaglandin A was determined by radioimmunoassay. The blood 




Res u1 ts 
The results of plasma and renal PGA determinations are shown 
in Table 5, and Figures 10 and 11. Student's t test was used for 
statistical analysis. 
High salt suppressed and low salt increased plasma and renal 
PGA concentrations significantly in both normal and spontaneously 
hypertensive rats. 
In the normotensive Wistar rats, plasma PGA levels on the high 
and low sodium diets differed significantly from the levels found 
in rats on the normal sodium intake (p < 0.001). Renal tissue PGA 
levels were also significantly altered on low and high sodium 
diets in comparison with normal sodium intake (p < 0.005 and 0.001 
respectively). 
In the spontaneously hypertensive Aoki rats plasma PGA levels 
on the low and high sodium diets differed significantly from the 
levels found in these hypertensive rats on the normal sodium diet 
(p < 0.02 and 0.04 respectively). Renal tissue PGA levels were 
also significantly altered on low and high sodium diets in comparison 
with normal sodium intake (p < 0.01 and 0.002 respectively). 
Moreover plasma PGA levels were significantly higher in the 
spontaneously hypertensive rats in comparison with the normotensive 
rats on each diet, p values were less than 0.005, 0.02, and 0.001 on 
the low, normal, and high sodium diets respectively. Similarly 
renal PGA levels were higher in the spontaneously hypertensive rats, 




Linear regression analysis (Figure 3) of plasma versus renal 
PGA levels revealed a very high degree of correlation (regression 
coefficient = 0.891, p less than 0.001) in both the spontaneously 
hypertensive and normotensive rats. 
Blood pressure did not significantly change in any of the 
rats on the three sodium intake diets. 
There was no significant difference in the food intake of 
the rats on the high, low, and normal sodium intake diets. The 
rats drinking 0.9% NaCl took in 20-70 ml/day with a mean of 40 ml/day, 
resulting in a mean additional intake of 6 mEq of sodium per day. 
There was no significant difference in the rate of weight gain or 
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EFFECT OF SODIUM INTAKE ON PLASMA PROSTAGLANDIN A 
SODIUM CONTENT OF DIET, mEq / kg 
Figure 10. Plasma prostaglandin A levels in hypertensive and normotensive 






















EFFECT OF SODiUM INTAKE ON RENAL PROSTAGLANDIN A 
SODIUM CONTENT OF DIET, mEq/kg 
Figure 11. Renal prostaglandin A levels in hypertensive and normotensive 




























CORRELATION OF PLASMA AND RENAL PROSTAGLANDIN A 
PLASMA PROSTAGLANDIN A, ng/ml 
Figure 12. Correlation of plasma and renal prostaglandin A levels in 
hypertensive and normotensive rats on high, low, and normal 




The results of these studies show that in both the normal 
human and the spontaneously hypertensive or normotensive Wistar 
rat changes in dietary sodium intake influence plasma PGA levels. 
In the normal human it was shown that there are no changes in 
circulating PGE or PGF levels. This observation does not however, 
exclude the possibility of renal changes in PGE or PGF since 
metabolism of the E and F prostaglandins by the pulmonary 
circulation would prevent observation of such changes in the 
peripheral plasma. Furthermore, the observation in the rats 
that the plasma changes in PGA levels are parallelled by changes 
within the renal parenchyma suggest that both PGA synthesis and 
release is increased by sodium restriction and decreased by sodium 
loading. 
These experiments do not elucidate the source of circulating 
prostaglandin A, however, it seems likely that the kidney contributes 
to the plasma levels. Prostaglandins A, E, and F have been found 
in the renal medulla and prostaglandin-like substances have been 
shown to be released from the kidney in response to several 
types of physiologic stimuli. The close correlation (regression 
coefficient = 0.891, p less than 0.001) observed between the plasma 
and renal PGA levels in the rat studies certainly suggests that 
plasma PGA levels are effected by changes in renal PGA synthesis 
and release. 
It is significant to note that the plasma and renal concentrations 
of PGA in the spontaneously hypertensive rats were higher than in 
- 
the normotensive Wistar rats in each dietary group. It is possible 
that PGA, a potent vasodilator, is released as a compensatory 
response in the spontaneously hypertensive rat. It is also possibl 
that intrarenal stimuli, perhaps vascular spasm or local ischemia, 




PROSTAGLANDIN A LEVELS IN HYPERTENSIVE HUMANS 
The evidence that the kidney plays an antihypertensive 
function and that prostaglandins may play an important role in 
protecting the “normal" blood pressure has been reviewed previously 
in the introduction to this thesis. Studies in the spontaneously 
hypertensive rat have shown that these animals have increased 
plasma and renal levels of prostaglandin A suggesting that there 
is a compensatory release of this potent vasodilator in an 
attempt to lower blood pressure from its abnormal elevation. 
In studies by Westura et.al. (1970) and Lee, et.al. (1971) 
it was shown that the intravenous administration of prostaglandin A-j 
to patients with essential hypertension resulted in lower blood 
pressure without marked alteration in renal blood flow and sodium 
homeostasis. These observations, along with studies which 
have shown that intra-arterial administration of prostaglandin A 
increased blood flow to the coronary, carotid, femoral, brachial, 
mesenteric, pulmonary, cutaneous, and renal circulations (Nakano, 1968; 
Nakano and McCurdy, 1967, 1968; Hauge, et.al., 1967; Lee, 1968) 
led Lee to suggest that a deficiency of prostaglandin A in the 




Lee has postulated that a deficiency of circulating PGA 
may alter vasomotor tone in two possible manners. First, a 
deficiency in arterial PGA levels may result in an increased 
vasomotor tone due to the lack of the normal vasodilating effect 
of the prostaglandins on the vasculature. Second, a deficiency 
of intrarenal and circulating prostaglandin may result in relative 
cortical ischemia resulting in the release of increased quantities 
of renin, with the resultant increase in circulating angiotensin II. 
Either or both of these mechanisms may play a role in the pathogenesis 
of hypertensive states, in particular the development of essential 
hypertension. 
Materials and Methods 
Twenty-three subjects were evaluated as patients in the Yale- 
New Haven Hospital. Hypertensive medications, diuretics, and 
potassium supplements were discontinued approximately 14 days prior 
to evaluation. All patients underwent complete physical examination 
and laboratory evaluation which included urine analysis and culture, 
serum blood urea nitrogen, creatinine, sodium, potassium chloride, 
and bicarbonate, plasma cortisol, twenth-four hour catecholamine, 
17-hydroxy steroid, and 17-keto steroid urinary excretion, chest 
X-ray, EKG, and rapid sequence intravenous pyelography. The 
diagnosis of essential hypertension was made in those patients with 
no evidence of adrenal hypertension, parenchymal renal disease, renal 
artery stenosis or excess catecholamine excretion. The diagnosis of 
renal artery stenosis was made on the basis of intravenous pyelography 
and renal arteriography. 
. 
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Blood was collected in vacutainers containing heparin or 
EDTA as the anticoagulant and was centrifuged at 4°C (2200 x g) 
to remove the red cells. Plasma was stored at -20°C until 
radioimmunoassay for renin activity and prostaglandin A. 
Results 
ESSENTIAL HYPERTENSION 
Table 6 shows the age, sex, blood pressure, daily sodium intake, 
plasma renin activity,and peripheral prostaglandin A level in the 
14 patients with essential hypertension. Figure 13 shows a 
comparison of these patients' PGA levels with normal humans on low, 
high, and ad-lib sodium intake diets. 
There were 8 male and 6 female subjects; the mean age was 
47.7 years, range 24 - 84. Mean PGA levels were 0.60 + 0.07 ng/ml, 
range 0.03 - 0.98. These levels are markedly depressed in comparison 
to normal humans on ad-lib or sodium restricted diets, p less than 
0.001 in each case. 
HYPERTENSION SECONDARY TO RENAL ARTERY STENOSIS 
Table 7 shows the age, sex, blood pressure, daily sodium 
intake, plasma renin activity, and prostaglandin A levels in 9 patients 
with hypertension associated with renal artery stenosis. Prosta¬ 
glandin A levels were determined in the peripheral plasma in all 
9 subjects. In 8 subjects PGA was measured in renal venous blood. 
The sample designated as ipsalateral represents the renal vein 
of the kidney with the renal artery stenosis; the contralateral 
■ 
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sample refers to the renal vein from the “normal" kidney. 
There were 4 male and 5 male subjects, mean age 40.4 years, 
range 11 - 65. Peripheral plasma PGA levels were 0.69 + 0.07 ng/ml 
(mean + SEM), range .24 - .96. These levels are markedly depressed 
in comparison to normal humans on ad-lib or sodium restricted diets 
(Figure 13), p less than 0.001 in each case. 
In all 8 subjects in which renal venous samples were available 
there were greater levels of PGA in the renal venous plasma from 
both the ipsalateral and contralateral kidneys in comparison with 
the peripheral PGA levels. Ipsalateral venous values were 1.23 +0.26 
ng/ml; or 172.7 +^31.8% of the peripheral value, p less than 0.05. 
Contralateral venous values were 1.61 +0.30 ng/ml; or 225.7 +38.3% 
of the peripheral value, p less than 0.Q2. Contralateral venous 
values were significantly elevated in comparison with the ipsalateral 
values, p less than 0.002. 
CORRELATION OF PLASMA PROSTAGLANDIN A AND RENIN ACTIVITY 
Figure 14 shows a comparison of peripheral plasma renin 
activity and prostaglandin A level. In the studies on the effect 
of sodium intake on plasma prostaglandin A levels in normal humans, 
plasma PGA and renin activity were shown to change in parallel 
fashion in response to changes in dietary sodium intake. In the 
hypertensive patients studied in this investigation the level of 
plasma PGA was inappropriately depressed when compared to their 
plasma renin levels. In 15 of 16 patients there was a significant 
discrepancy between the prostaglandin A concentration in the venous 
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COMPARISON OF PLASMA PROSTAGLANDIN A CONCENTRATIONS 
IN NORMOTENSIVE AND HYPERTENSIVE HUMANS 
Sodium No >200 
Intake mEq/day 






NORMOTENSIVE TENSION RENAL ARTERY 
( N = 7 ) (N = 14) STENOSIS 
(N =9) 
Figure 13. Comparison of plasma prostaglandin A levels in normal 
humans on high, low, and normal sodium intake diets 
and patients with essential hypertension or hypertension 























CORRELATION OF PERIPHERAL VENOUS PROSTAGLANDIN A 
AND RENIN ACTIVITY 
IN NORMAL AND HYPERTENSIVE HUMANS 
Figure 14. Comparison of plasma renin activity and prostaglandin A 




This study shows that hypertensive humans have a markedly 
depressed level of circulating prostaglandin A when compared with 
normal humans on a comparable sodium intake diet. Such decreased 
levels suggest a severe alteration in the normal mechanisms of 
prostaglandin synthesis and release in humans with elevated blood 
pressures secondary to renal artery stenosis or essential hypertension. 
These measurements confirm the predictions of Lee (1972a) with regard 
to the levels of circulating PGA in hypertensive humans. The 
previous observation that hypertensive rats have elevated rather than 
depressed PGA levels in comparison to normotensive rats presents a 
paradoxical situation. At present the only explanation available 
is that the response of the kidney to elevated blood pressure in these 
two organisms is different. 
The reason for the deficient circulating PGA levels in 
hypertensive humans is not clear at this time. It is possible that 
such patients have a primary defect in the mechanism regulating prosta¬ 
glandin synthesis and release thus resulting in lowered levels of 
circulating PGA, a potent vasodilator. As a result of these 
decreased levels there may be an increase in blood pressure to abnormal 
levels. It is also possible that the decrease in circulating PGA 
represents a secondary deficit; the result of damage by the elevated 
blood pressure to the mechanism which controls PGA synthesis and 
release. It is also possible that these patients metabolize PGA 
at an abnormally high rate. Present information is not sufficient 
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to distinguish between these three possible explanations for the 
decrease in circulating prostaglandin A. 
In previous studies, it has been shown that the infusion 
of angiotensin II into the renal artery resulted in the release 
of prostaglandin-like material into the renal venous effluent 
(McGiff, et.al., 1970a). Herbaczynaka-Cedro and Vane have shown 
that the blood pressure raising effect of intravenous angiotensin II 
is potentiated by prior administration of indomethacin, a potent 
prostaglandin synthesis inhibitor (1972). This observation suggests 
that prostaglandins play an important role in the modulation of 
changes in blood pressure in response to changes in angiotensin 
production. It is possible that the development of increased 
blood pressure in patients with essential hypertension or renal 
artery stenosis reflects not only an increase in vasopressor 
forces, but also the loss of the normal vasodepressor modulation 
performed by the prostaglandins, in particular prostaglandin A. 
The loss of the positive correlation between plasma renin activity 
and PGA content as shown in Figure 14 suggests that the normal 
interplay between these two vasotonic substances has been disturbed. 
It is possible that the loss of prostaglandin A as a vasodilator 
results in the further elevation of blood pressure in response 




THE ROLE OF PROSTAGLANDINS IN SODIUM HOMEOSTASIS 
The results of this study with respect to the effect of 
sodium intake on plasma levels of prostaglandin A in normal 
humans and spontaneously hypertensive and normotensive Wistar rats 
do not confirm the basic postulate of Lee's (1972b) theory regarding 
the role of prostaglandin A as a natriuretic hormone. According 
to his theory an increase in circulating prostaglandin A is associated 
with high sodium intake states and a reciprocal decrease in PGA with 
sodium restriction. Surprisingly our results show that sodium 
loading produces a marked depression and sodium restriction a 
marked elevation in circulating PGA. In order to explain these 
observations the following hypothesis is proposed for the role of 
prostaglandins in the control of sodium homeostasis (Figure 15). 
The observation that infusion of angiotensin II into the 
renal artery will result in the release of prostaglandin-like 
material into the renal venous effluent (McGiff, et. al., 1970a) 
suggests that angiotensin may be the physiologic factor which 
stimulates the release of prostaglandins linking them to the control 
of sodium excretion. Under conditions of sodium restriction, 
renin is released from the juxtaglomerular apparatus of the kidney 
and acts upon circulating angiotensinogen to result in increased 
levels of circulating angiotensin I which is then converted to 
angiotensin II by the converting enzyme of the lung (Mulrow and 
Goffinet, 1969). Increased angiotensin results in the release 

56 
of prostaglandins from the kidney. Enzyme systems recently 
identified in the kidney (Cammock, 1972) and in human plasma 
(McDonald-Gibson, McDonald-Gibson, and Greaves, 1972) are capable 
of converting prostaglandins of the E series to prostaglandins of 
the A series thereby resulting in an increase in the circulating 
level of PGA. Previous studies have shown that the major renal 
prostaglandin is actually prostaglandin E^ (Lee, et.al., 1967; 
Crowshaw and Szlyk, 1970; Crowshaw, et.al., 1970). In our own 
experience with human kidney tissue we found that prostaglandins 
of the E series made up greater than 60% of the total medullary 
prostaglandin content, with PGA making up only 15% of the total 
(Spector, et.al., 1973). It is therefore likely that the enzymatic 
conversion of PGE to PGA in the plasma is important and contributes 
to the resultant changes observed in the peripheral circulation. 
This increased circulating PGA will then antagonize the blood 
pressure increasing effects of the increased angiotensin II and 
thus prevent an increase in blood pressure. The studies by 
Herbaczynska-Cedro and Vane (1972) suggest that this release of 
prostaglandin is important in modulating the effect of increased 
angiotensin II concentrations. In their studies animals pretreated 
with indomethacin showed an increased blood pressure response to 
intravenous angiotensin II in comparison with the untreated controls. 
This same prostaglandin synthesis inhibitor had previously been 
shown to prevent the release of prostaglandins from the kidney in 
response to angiotensin II infusions (Aiken and Vane, 1971). 
"T* 
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It is, therefore, possible that prostaglandins do indeed play an 
important anti hypertensive role in this system. 
Studies by Fichman and colleagues (1972) have shown that 
intravenous infusion of prostaglandin A result in an increase in 
aldosterone release without measurable changes in ACTH, renin, or 
serum electrolytes. It is therefore possible that the increase 
in PGA serves also to stimulate the secretion of aldosterone, which 
tends to correct the original stimulus, i.e. sodium restriction, 
by causing increased reabsorption of sodium by the kidney. 
Finally there may be an intrarenal role for the prostaglandins 
in the control of hemodynamics within the kidney. Studies by 
Hollenberg and colleagues (1970, 1971, 1972a, and 1972b) have shown 
that there is a decrease in renal cortical blood flow in response 
to sodium restriction in man. Furthermore, alterations in 
distribution of intrarenal blood flow observed with sodium restriction 
are also noted with catecholamine infusion and renal nerve 
stimulation. Both these stimuli have previously been shown to 
result in the release of prostaglandin-like material into the renal 
vein. 
We have shown that there are changes in intrarenal concentrations 
of PGA in response to sodium restriction, parallelling the changes 
observed in the peripheral plasma. It is possible that the increase 
in medullary prostaglandins particularly A and E prostaglandins, may 
result in a medullary vasodilation and thus increased blood flow to 
the medullary region of the kidney at the expense of the cortical 
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region. This redistribution of renal blood flow may be important 
in the reabsorption of sodium by the medullary nephrons. Although 
there is no evidence that the cortex synthesizes prostaglandins, this 
region does have a very active enzyme system for prostaglandin 
metabolism (Nissen and Anderson, 1968 and 1969; Larsson and Anggard, 
1972; Anggard, et.al., 1971; Crowshaw, et.al., 1969, 1970). This 
suggests that intrarenal changes in prostaglandin levels have little 
or no effect upon the cortical circulation. 
In summary, it appears that prostaglandins are indeed 
"natriuretic" hormones, not in the sense of circulating natriuretic 
factors as originally postulated by Lee; but rather as intrarenal 
regulators of blood flow distribution. 
This intrarenal regulation of blood flow may be the controlling 
factor in the degree of sodium reabsorption by the renal nephron 
population. This hypothesis is schematically portrayed in Figure 15. 

J SODIUM REABSORPTION 
Figure 15. A possible mechanism for the control of prostaglandin 




PROSTAGLANDIN A AS A CIRCULATING ANTI-HYPERTENSIVE HORMONE 
In order to determine the role of prostaglandin A as an 
anti-hypertensive circulating hormone, plasma PGA levels were 
determined in both normal and hypertensive humans and rats. 
Somewhat paradoxically two different observations were made. 
In the Wistar rat strain, the hypertensive animal had significantly 
elevated levels of circulating prostaglandin A in comparison with 
the normotensive Wistar rat. This observation is best ascribed 
to a compensatory response by the hypertensive animal, the release 
of a potent vasodilator in an attempt to lower the elevated blood 
pressure. On the other hand in the human, hypertensive subjects 
with either essential hypertension or hypertension secondary to 
renal artery stenosis showed markedly depressed levels of circulating 
prostaglandin A. It is possible that the development of high blood 
pressure in some cases of essential hypertension represents the 
natural course of a deficiency in prostaglandin synthesis and 
release. Indeed, it may be that essential hypertension is a result 
of hypoprostaglandinemia, as originally suggested by Lee, and that 
the restoration of normal plasma levels may be of therapeutic 
value. 
THE KIDNEY AS THE SOURCE OF CIRCULATING PROSTAGLANDIN A 
Although many investigators have suggested that the source 
of circulating prostaglandin A is the kidney it has been impossible 
until this time to verify or refute this suggestion. This investigation 
has produced evidence which would seem to substantiate the proposal 




circulating prostaglandin A. 
As previously noted prostaglandins A£, E£ and have been 
identified in renal medullary tissue (Lee, 1972a) and renal 
interstitial cells have been shown to produce these prostaglandins 
when grown in tissue culture (Muirhead, et.al., 1972b). Our studies 
with rats indicating a close correlation between plasma and renal 
prostaglandin A concentrations under varying sodium intake diets 
suggest that the kidney is responsible for the changes seen in these 
experiments. The marked depression of PGA levels in anephric 
patients in comparison with PGA levels observed in normal and 
hypertensive humans suggest that the kidney contributes a major 
portion of the circulating PGA in human plasma. The observation 
in patients with renal artery stenosis that renal venous plasma had 
higher levels of PGA than peripheral plasma also seems to substantiate 
the suggestion that the kidney does indeed contribute a major 
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